|
Open Access-Title
|
Case series of inflammatory breast cancer in two Greek hospitals: our experience and critical appraisal |
|
|
Author
|
Alexios-Fotios Mentis, Stefanos Zervoudis, Georgios Papadopoulos, Christos Spanopoulos, Mirsini Balafouta, Georgios Tsakiris, Anastasia Bothou, Juan Jiménez, Irene Garcia, Panagiotis Tsikouras, Georgios Iatrakis, Nikolaos Nikolettos University Research Institute of Maternal and Child Health & Precision Medicine, and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Aghia Sophia Children’s Hospital, Athens, Greece. |
|
|
Citation
|
A-F. Mentis, S. Zervoudis, G. Papadopoulos, C. Spanopoulos, M. Balafouta, G. Tsakiris, A. Bothou, J. Jiménez, I. Garcia, P. Tsikouras, G. Iatrakis, N. Nikolettos. Case series of inflammatory breast cancer in two Greek hospitals: our experience and critical appraisal. Review Clin. Pharmacol. Pharmacokinet. 2021, 35, 3, 95-102. DOI:10.5281/zenodo.10048312 |
|
|
Publication Date
Republication Date
|
22-11-2021
27-10-2023
|
|
|
Full Text Language
|
English |
|
|
DOI:10.5281/zenodo.10048312 |
||
|
Keywords
|
Cancer; Breast cancer; Inflammatory breast cancer; Metastasis; Neoadjuvant chemotherapy; Greece
|
|
|
Other Terms
|
Original Article |
|
|
Summary
|
Inflammatory breast cancer (IBC) represents a very aggressive type of locally advanced cancer. Because of its rarity, management of IBC appears heterogeneous; thus, reporting experiences from different clinics can be helpful. Fourteen female patients with IBC in two clinics of Greek hospitals were included in this case series study. The type of surgery performed in the eight patients that underwent surgery was modified radical mastectomy after neoadjuvant chemotherapy. Moreover, lymph node excision (level one and two) was performed in all (n=14) patients; all but one patients had positive lymph nodes. Sentinel biopsy technique was avoided in the above female patients with IBC. Radiotherapy was applied to all patients, except one elderly patient. Second-line chemotherapy was applied in three patients with aggressive, recurrent tumors. Two patients out of 14 (~14.3%) died within 3 years after initial treatment, 2 patients are alive (~14.3%) with recurrence after 5 years, and 10 patients are still alive (~71.4%) with no clinically apparent recurrence. Four patients (~28.6%) had local recurrence; among them, two (~14.3% out of total) were treated with lumpectomy, and two (~14.3%) were diagnosed with distant metastasis. Second line chemotherapy was applied to 4 (~28.6%) patients. In addition, IBC cases represented around 2% of the total number of female patients with breast cancer in our centers. Patients with IBC who were treated with multimodal management (i.e., chemotherapy and surgical treatment) did not have higher disease-free survival rates compared to those treated with chemotherapy alone. According to our experience, and in contrast to the typical low prognosis of IBC, the aggressive management of patients with IBC leads to relatively high prognosis rates and high level of disease-free survival in our case series. This approach needs to be assessed in larger clinical settings within the broader aim of exploring potential new approaches in management of patients with IBC. | |
| References | [1] Abraham H.G., Xia Y., Mukherjee B., Merajver S.D.: Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Res Treat. 185(1): 229-238 (2021).[2] Boussen H., Bouzaiene H., Ben Hassouna J., Dhiab T., Khomsi F., Benna F., Gamoudi A., Mourali N., Hechiche M., Rahal K.: Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer 116(S11): 2730-2735 (2010).[3] Lee B.J.: Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 39: 580-59 (1924).[4] Kleer C.G., van Golen K.L., Merajver S.D.: Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2(6): 1-7 (2000).[5] Van Laere S., Limame R., Van Marck E.A., Vermeulen P.B., Dirix L.Y.: Is there a role for mammary stem cells in inflammatory breast carcinoma? A review of evidence from cell line, animal model, and human tissue sample experiments. Cancer 116(S11): 2794-2805 (2010).
[6] Radunsky G.S., van Golen K.L.: The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis 22(8): 615-20 (2005). [7] Singletary S.E., Connolly J.L.: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA: a cancer journal for clinicians 56(1): 37-47 (2006). [8] Zervoudis S., Iatrakis G., Tomara E., Bothou A., Papadopoulos G., Tsakiris G.: Main controversies in breast cancer. World J Clin Oncol 5(3); 359-73 (2014). [9] Dawood S., Merajver S., Viens P., Vermeulen P., Swain S., Buchholz T., Dirix L., Levine P., Lucci A., Krishnamurthy S.: International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of oncology 22(3); 515-523 (2011). [10] Bertucci F., Finetti P., Birnbaum D., Viens P.: Gene expression profiling of inflammatory breast cancer. Cancer 116(S11); 2783-2793 (2010). [11] Kleer C.G., Zhang Y., Pan Q., Gallagher G., Wu M., Wu Z.-F., Merajver S.D.: WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Research 6(2); 1-6 (2004). [12] Sutherland S., Ashley S., Walsh G., Smith I.E., Johnston S.R.: Inflammatory breast cancer—the Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. Cancer 116(S11); 2815-2820 (2010). [13] Tai P., Yu E., Shiels R., Pacella J., Jones K., Sadikov E., Mahmood S.: Short-and long-term cause-specific survival of patients with inflammatory breast cancer. BMC cancer 5(1); 1-10 (2005). [14] Iatrakis G., Zervoudis S., Ceausu I., Peitsidis P., Tomara I., Bakalianou K., Hudita D.: Clinical features and treatment of lactational mastitis: the experience from a binational study. Clin Exp Obstet Gynecol 40(2); 275-6 (2013). [15] Zervoudis S., Iatrakis G., Daures J.P., Bothou A., Aranitis V., Patralexis X., Tsatsaris G., Navrozoglou I., Tsikouras P., Paschopoulos M.: Ductoscopy Coupled to Duct Lavage and Duct Brushing in Pathologic Nipple Discharge: Our Experience. Chirurgia (Bucur). 115(3); 334-340 (2020). [16] Zervoudis S., Iatrakis G., Mares P., Boileau L., Grammatikakis I., Evangelinakis N., Daures J.P., Leteuff I., Avgoulea A., Stefos T., Navrozoglou I.: Breast conserving surgery in multicentric breast cancer, preliminary data of our experience. Eur J Gynaecol Oncol. 35(5); 530-4 (2014). [17] Zervoudis S., Xepapadakis G., Psarros N., Bothou A., Tsikouras P., Galazios G., Kontogianni P., Papazian M., Navrozoglou I., Iatrakis G., Paschopoulos M.: Management of malignant and borderline phyllodes tumors of the breast: our experience. J Buon. 24(4); 1521-1525 (2019). [18] White R.E., Warren L., Nakhlis F., Rosenbluth J., Bellon J., Block C., Overmoyer B.: Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program. The Breast Journal 26(9); 1688-1694 (2020). [20] Scott L., Mobley L.R., Il’yasova D.: Geospatial analysis of inflammatory breast cancer and associated community characteristics in the United States. Int J Environ Res Public Health 14(4); 404 (2017). [21] Liu Y.L., Wang D.W., Yang Z.C., Ma R., Li Z., Suo W., Zhao Z., Li Z.W.: Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 178(2); 379-388, (2019). [22] Bothou A., Zervoudis S., Tsatsaris G., Iatrakis G., Deuteraiou D., Anthoulaki X., Galazios G., Tsikouras P.: Maternal and paternal age at birth and the risk of breast cancer in Greek women: a case-control study. J BUON. 25(2); 662-665 (2020). [23] Lerebours F., Bieche I., Lidereau R.: Update on inflammatory breast cancer. Breast Cancer Res 7(2) 52-8 (2005). [24] Chang S., Parker S.L., Pham T., Buzdar A.U., Hursting S.D.: Inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer 82(12); 2366-2372, (1998). [25] Harris E.E., Schultz D., Bertsch H., Fox K., Glick J., Solin L.J.: Ten-year outcome after combined modality therapy for inflammatory breast cancer. I Int J Radiat Oncol Biol Phys. 55(5); 1200-1208 (2003). [26] Somlo G., Frankel P., Chow W., Leong L., Margolin K., Morgan R.Jr., Shibata S., Chu P., Forman S., Lim D., Twardowski P., Weitzel J., Alvarnas J., Kogut N., Schriber J., Fermin E., Yen Y., Damon L., Doroshow J.H.: Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol 22(10); 1839-48 (2004). [27] Raghav K., French J., Ueno N., Lei X., Krishnamurthy S., Reuben J., Valero V., Ibrahim N.: Inflammatory breast cancer: A distinct clinicopathological entity transcending histological distinction, PloS one 11(1) e0145534 (2016). [28] Silberholz J., Bertsimas D., Vahdat L.: Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis. Breast Cancer Res Treat. 176(3) 535-543 (2019). [29] D’Alessandro C., Dellapasqua S., Orlando L., Santoro L., Maisonneuve P., Torrisi R., Balduzzi A., Scarano E., Ghisini R., Peruzzotti G., Goldhirsch A., Colleoni M.: Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J 14(5); 435-41 (2008). [30] Dawood S., Cristofanilli M.: Inflammatory breast cancer: what progress have we made? Oncology (Williston Park) 25(3); 264-70, 273 (2011). [31] Li Z.W., Zhang M., Yang Y.J., Zhou Z.J., Liu Y.L., Li H., Bao B., Diao J.D., Wang D.W.: Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study. PeerJ 8; e8512 (2020). [32] Levine P.H., Steinhorn S.C., Ries L.G., Aron J.L.: Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 74(2); 291-7 (1985). [33] Piera J., Alonso M., Ojeda M., Biete A.: Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol. 7(3); 199-204 (1986). [34] Galmarini C.M., Garbovesky C., Galmarini D., Galmarini F.C.: Clinical outcome and prognosis of patients with inflammatory breast cancer. Am J Clin Oncol 25(2); 172-7 (2002). [35] Diao J.D., Ma L.C., Sun M.Y., Wu C.J., Wang L.J., Liu Y.L., Yang Y.J.: Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer. Cancer medicine 8(12); 5600-5608 (2019). [36] Pan X., Yang W., Chen Y., Tong L., Li C., Li H: Nomogram for predicting the overall survival of patients with inflammatory breast cancer: a SEER-based study. The Breast 47; 56-61 (2019). [38] Ross J.S.: Measuring circulating miRNAs: the new “PSA” for Breast Cancer?, Oncologist 15(7); 656 (2010). [39] Diaz A., Dalmacy D., Herbert C., Mirdad R.S., Hyer J.M., Pawlik T.M.: Association of County-Level Racial Diversity and Likelihood of a Textbook Outcome Following Pancreas Surgery. Annals of surgical oncology 28(13); 8076-8084 (2021). [40] Telonis AG, Loher P., Magee R., Pliatsika V., Londin E., Kirino Y., Rigoutsos I.: tRNA fragments show intertwining with mRNAs of specific repeat content and have links to disparities. Cancer Res. 79(12); 3034-3049 (2019). [41] Telonis A.G., Rigoutsos I.: Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer. Cancer Res. 78(5); 1140-1154 (2018). [42] Jackson C.L., Szklo M., Yeh H.C., Wang N.Y., Dray-Spira R., Thorpe R., Brancati F.L.: Black-white disparities in overweight and obesity trends by educational attainment in the United States, 1997-2008. J Obes 2013; 140743 (2013). [43] Clarke P., O’Malley P.M., Johnston L.D., Schulenberg J.E.: Social disparities in BMI trajectories across adulthood by gender, race/ethnicity and lifetime socio-economic position: 1986-2004. Int J Epidemiol 38(2); 499-509 (2009). [44] Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., MacGrogan G., Bergh J., Cameron D., Goldstein D.: Identification of molecular apocrine breast tumours by microarray analysis. Breast Cancer Res. 7(2); 1-1 (2005). [45] Davis M.B.: Genomics and Cancer Disparities: The Justice and Power of Inclusion. Cancer Discov. 11(4); 805-809 (2021). [46] Desai A., Gyawali B.: Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine 20; 100269 (2020). |
|
|
Relative Papers
|
Online ISSN 1011-6583
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor
Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors
Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition
Συντακτικη Επιτροπή-Editorial Board